Join the Biomedical Advanced Research and Development Authority (BARDA) and FDA tomorrow for a workshop, which will provide: 1) a forum for product sponsors to discuss progress and technical challenges in the manufacturing when changing strain composition to currently circulating variants of SARS-CoV-2; and 2) an open forum for collaborative discussions to facilitate advancement of recombinant protein-based COVID-19 vaccines. (Agenda)